Insider Sale: NEUROONE (NMTC) Director Disposes of 253 Shares

Rhea-AI Filing Summary

Insider sale reported: Mark Christianson, Business Development Director of NeuroOne Medical Technologies (NMTC), reported a disposition of 253 shares of the company's common stock on 09/30/2025 at a reported price of $0.8886 per share. After the transaction he beneficially owns 230,985 shares in a direct capacity. The Form 4 was signed by Emily Johns by power of attorney on 10/01/2025. The filing indicates the report was made by one reporting person and lists Christianson\'s Eden Prairie, MN address.

Positive

• Timely disclosure of insider transaction with transaction date, price, and post-transaction holdings provided
• Small transaction size (253 shares) relative to total reported holdings, suggesting limited material impact

Negative

• Insider disposition of shares was reported, which some investors may view negatively despite small size

Insights

Financial Analyst

TL;DR: A small, disclosed insider sale of 253 shares reduces direct holdings to 230,985 shares; transaction appears routine and was timely reported.

The reported disposition of 253 shares at $0.8886 is small relative to the total reported holding of 230,985 shares (approximately 0.11%). This size suggests the transaction is unlikely to materially affect ownership concentration or company valuation. The Form 4 provides clear transaction date and price details, supporting transparency in insider activity.

Corporate Governance Expert

TL;DR: Disclosure compliance is satisfied; the Form 4 documents a direct sale by a named officer and is properly executed via power of attorney.

The filing names Mark Christianson as Business Development Director and shows a direct beneficial ownership change. The Form 4 was executed via power of attorney, which is permitted when properly authorized. The filing meets basic Section 16 disclosure requirements by specifying the transaction code, price, and post-transaction holdings.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Christianson Mark

(Last) (First) (Middle)

7599 ANAGRAM DR.

(Street)

EDEN PRAIRIE MN 55344

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
NEUROONE MEDICAL TECHNOLOGIES Corp [ NMTC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Business Development Director

3. Date of Earliest Transaction (Month/Day/Year)
09/30/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/30/2025		F		253	D	$0.8886	230,985	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Emily Johns, by Power of Attorney	10/01/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did NEUROONE MEDICAL TECHNOLOGIES (NMTC) report?

Mark Christianson reported a disposition of 253 shares of common stock on 09/30/2025 at a reported price of $0.8886 per share.

How many shares does Mark Christianson own after the reported transaction?

Following the reported transaction, Christianson beneficially owns 230,985 shares in a direct capacity.

What role does the reporting person hold at NMTC?

The Form 4 lists Mark Christianson as Business Development Director and indicates he is an officer.

When was the Form 4 signed and by whom?

The Form 4 includes a signature by Emily Johns, by Power of Attorney dated 10/01/2025.

What transaction code is shown on the filing?

The filing shows transaction code F for the reported disposition on 09/30/2025.